Cargando…
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systemat...
Autores principales: | Hirte, Hal, Poon, Raymond, Yao, Xiaomei, May, Taymaa, Ethier, Josee-Lyne, Petz, Lauri, Speakman, Jane, Elit, Laurie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774918/ https://www.ncbi.nlm.nih.gov/pubmed/35049696 http://dx.doi.org/10.3390/curroncol29010022 |
Ejemplares similares
-
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma
por: Hirte, Hal, et al.
Publicado: (2021) -
FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
por: Prat, Jaime
Publicado: (2015) -
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
por: Elit, Laurie, et al.
Publicado: (2013) -
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
por: Tokunaga, Hideki, et al.
Publicado: (2021) -
Optimal chemotherapy treatment for women with recurrent ovarian cancer
por: Fung-Kee-Fung, M., et al.
Publicado: (2007)